A multi-center, randomized, double-blind, parallel-group, placebocontrolled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequency exacerbations and characterized by eosinophil levels (Study 208657)

To evaluate the efficacy of mepolizumab 100 mg subcutaneous (SC) compared to placebo, given every 4 weeks in liquid
formulation by safety syringe (SS) to COPD participants at high risk of exacerbations despite the use of optimized COPD maintenance therapy.